Patents by Inventor Luke Lairson

Luke Lairson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
    Patent number: 11246873
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: February 15, 2022
    Assignee: The Scripps Research Institute
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • METHODS FOR PROMOTING MYELINATION AND FOR TREATING DEMYELINATING DISEASES
    Publication number: 20210023218
    Abstract: This invention provides novel methods for treating or ameliorating symptoms of demyelinating diseases such as multiple sclerosis. The methods involve administering to subjects in need of treatment a pharmaceutical composition that contains a therapeutically effective amount of taurine and also a compound that induces oligodendrocyte precursor cell (OPC) differentiation (e.g., T3, benztropine, clemastine or miconazole). Some of the methods additionally involve administration to the subject a known agent for treating demyelinating diseases (e.g., SIP receptor agonists) or a known disease modifying drug. The invention also provides methods for increasing myelination and methods for promoting OPC differentiation into oligodendrocytes. These methods entail contacting a population of OPCs with a combination of taurine and a known OPC differentiation-inducing agent such as T3, clemastine, benztropine or miconazole.
    Type: Application
    Filed: November 13, 2018
    Publication date: January 28, 2021
    Inventors: Luke Lairson, Brittney Beyer, Mingliang Fang, Gary Siuzdak
  • DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
    Publication number: 20200390780
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Application
    Filed: April 8, 2020
    Publication date: December 17, 2020
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
    Patent number: 10660899
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: May 26, 2020
    Assignees: The Scripps Research Institute, Novartis AG
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
    Patent number: 10493080
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: December 3, 2019
    Assignees: The Scripps Research Institute, Novartis AG
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Small molecule inhibitors of fibrosis
    Patent number: 10336735
    Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: July 2, 2019
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Luke Lairson, Arnab K. Chatterjee, Michael Bollong, Baiyuan Yang, Peter G. Schultz
  • Small molecule inhibitors of fibrosis
    Patent number: 9981956
    Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: May 29, 2018
    Assignees: The Scripps Research Institute, The California Institute for Biomedical Research
    Inventors: Luke Lairson, Michael Bollong, Peter G. Schultz, Arnab K. Chatterjee, Baiyuan Yang, Puneet Kumar, Kaveri Urkalan
  • SMALL MOLECULE INHIBITORS OF FIBROSIS
    Publication number: 20170362211
    Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.
    Type: Application
    Filed: December 9, 2015
    Publication date: December 21, 2017
    Inventors: Luke LAIRSON, Arnab K. CHATTERJEE, Michael BOLLONG, Baiyuan YANG, Peter G. SCHULTZ
  • SMALL MOLECULE INHIBITORS OF FIBROSIS
    Publication number: 20170217943
    Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Inventors: Luke LAIRSON, Michael BOLLONG, Peter G. SCHULTZ, Arnab K. CHATTERJEE, Baiyuan YANG, Puneet KUMAR, Kaveri URKALAN
  • Small molecule inhibitors of fibrosis
    Patent number: 9663499
    Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: May 30, 2017
    Assignees: The California Institute for Biomedical Research, The Scripps Research Institute
    Inventors: Luke Lairson, Michael Bollong, Peter G. Schultz, Arnab K. Chatterjee, Baiyuan Yang, Puneet Kumar, Kaveri Urkalan
  • DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
    Publication number: 20170136029
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 18, 2017
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
    Patent number: 9592288
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: March 14, 2017
    Assignees: The Scripps Research Institute, IRM LLC
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
    Publication number: 20160166687
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 16, 2016
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • SMALL MOLECULE INHIBITORS OF FIBROSIS
    Publication number: 20160130258
    Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.
    Type: Application
    Filed: June 5, 2014
    Publication date: May 12, 2016
    Inventors: Luke LAIRSON, Michael BOLLONG, Peter G. SCHULTZ, Arnab K. CHATTERJEE, Baiyuan YANG, Puneet KUMAR, Kaveri URKALAN
  • DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
    Publication number: 20140038949
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Application
    Filed: February 17, 2012
    Publication date: February 6, 2014
    Applicants: IRM LLC, The Scripps Research Institute
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis